Radiopharm (ASX: RAD) gets approval for Phase 1 PDL1-nanobody study in NSCLS

October 09, 2023 01:10 PM AEDT | By Sonal Goyal

Google News:

Radiopharm (ASX: RAD) gets approval for Phase 1 PDL1-nanobody study in NSCLS — Image source: Company website

Recent News

Gold Resource Corporation Adds to Board of Directors

Southern Company Supports Veterans’ Transition to Civilian Careers Thr...

DaVita Releases Annual Community Care Report, Highlights Achievements...

T‑Mobile’s Hometown Grants Program Delivers Nearly $18M in Lasting Cha...

Highlights

HREC approval enables conducting a Phase 1 therapeutic study in patients with PDL1-positive NSCLC.

GenesisCare Contract Research Organization would support the study.

NSCLC is the most common type of lung cancer.

Radiopharm Theranostics Limited (ASX: RAD) has received Human Research Ethics Committee (HREC) approval to undertake a Phase 1 therapeutic study in patients with PDL1- positive non-small cell lung cancer (NSCLC). This is the company’s first-in-human Phase 1 study in Australia for its therapy in this condition.

The dose escalation trial of RAD204 aims to assess the efficacy and safety of this radiotherapeutic in patients with PDL1-positive NSCLC.

The study would take place at Alexandra Hospital in Brisbane, Australia, with the assistance of GenesisCare, an oncology care provider.

Data source: Company update

Shares jump

Triggered by the update, RAD’s share price increased by 3.85% to trade at AU$0.14 apiece at the time of writing on 9 October 2023.

More

RAD’s proprietary nanobody from the NanoMab platform is the technology which underpins the Phase 1 therapeutic study, targeting PDL1-positive NSCLC, the most common type of lung cancer.

The company highlighted that in Australia, around 12,200 patients are diagnosed with lung cancer annually, making it the fifth most common cancer in the nation. Globally, in 2020, over 2.2 million lung cancer cases were reported, out of which NSCLC accounted for ~85% of the cases.

This is an area of high unmet need and there is potential for the treatment to be the “first in class” radiopharmaceutical therapy targeting PDL1, indicates the company.

To know about RAD’s annual performance in 2023, click here.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.